Immunis, Inc., a clinical-stage biotech company targeting age-related diseases, today announced it has entered an exclusive licensing agreement with Toray to develop and commercialize a drug candidate for the treatment of dyskinesia associated with Parkinson’s disease. Immunis will continue its development under the name “IMM02‑KORA” or “KORA.”

Under the terms of the agreement, Immunis obtained exclusive rights to develop and commercialize “KORA” in the United States, Canada, the European Union, and the European Free Trade Association. Immunis has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial.

Published preclinical data show that KORA effectively reduces L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson’s disease, supporting Immunis’ clinical development plan.

According to the World Health Organization, the prevalence of Parkinson’s disease has doubled within the past 25 years, and The Global Burden of Disease estimates that 1.3 million people are diagnosed with Parkinson’s disease annually.^1,2 An estimated 80% of individuals with Parkinson’s disease receiving the current standard of care will develop dyskinesia within 10 years, which can severely impact daily activities such as writing, eating, and dressing and can increase the risk of falls and social isolation.³

“Immunis is thrilled to expand our research pipeline to include a common and serious complication affecting Parkinson’s disease patients,” said Mark Cabato, Chief Business Officer at Immunis. “Our collaboration with Toray reflects our continued commitment to maximizing healthspan and minimizing disease through the advancement of transformative medicine.”

Resources:

1. World Health Organization. (2023, August 9). “Parkinson disease.” https://www.who.int/news-room/fact-sheets/detail/parkinson-disease.
2. Luo, Yuanrong, Lichun Qiao, Miaoqian Li, Xinyue Wen, Wenbin Zhang, and Xianwen Li. “Global, Regional, National Epidemiology and Trends of Parkinson’s Disease from 1990 to 2021: Findings from the Global Burden of Disease Study 2021.” Frontiers in Aging Neuroscience 16 (January 2025): 1498756. https://doi.org/10.3389/fnagi.2024.1498756.
3. Leal, Denisson Augusto Bastos, Carla Michele Vieira Dias, Rodrigo Pereira Ramos, and Ivani Brys. “Prediction of Dyskinesia in Parkinson’s Disease Patients Using Machine Learning Algorithms.” Scientific Reports 13, no. 1 (2023): 22426. https://doi.org/10.1038/s41598-023-49617-w.

About Toray

Toray Industries, Inc. is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray has continuously expanded its business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with its Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” the company will commit to delivering fundamental solutions to global-scale challenges.

About Immunis, Inc.

Immunis is a clinical-stage biotech developing a clinically advanced, first-in-class stem cell-derived secretome product targeting the underlying factors of aging that drive muscle and metabolic disease. IMM01-STEM is an investigational product, a complex biologic comprised of regenerative factors that impact multiple signaling pathways. Immunis is dedicated to maximizing health span and to minimizing disease through the advancement of transformative medicine.

For additional information about Immunis’ programs, please visit:

Immunisbiomedical.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry, which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Press Contact

Shira Derasmo, Cuttlefish Communications

917-280-2497 | shira@cuttlefishpr.com

Investor Relations Contact

Mark Cabato, Chief Business Officer, Immunis, Inc.

mark@immunisbiomedical.com